Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures

Overview of attention for article published in Journal of Hematology & Oncology, July 2012

Altmetric Badge

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 47 Mendeley

Summary Dimensions citations

So far, Dimensions has found 35 publications that cite this research output.

35

The most recent citing publications are shown below. View all 35 publications that cite this research output on Dimensions.

Revealing metastatic castration‐resistant prostate cancer master regulator through lncRNAs‐centered regulatory network

Article in Cancer Medicine (August 2023)

Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials

Article in European Urology (February 2023)

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses

Article in The Oncologist (September 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.